PNC Financial Services Group
MRSN

PNC Financial Services Group’s Mersana Therapeutics MRSN Stock Holding History

PNC Financial Services Group’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-36
Closed -$264 – 5175
2025
Q2 		$264 Sell
36
-105
-74% -$923 ﹤0.01% 4776
2025
Q1 		$1.22K Buy
141
+133
+1,663% +$2.05K ﹤0.01% 4485
2024
Q4 		$286 Hold
8
– – ﹤0.01% 4605
2024
Q3 		$378 Hold
8
– – ﹤0.01% 4602
2024
Q2 		$402 Hold
8
– – ﹤0.01% 4559
2024
Q1 		$896 Hold
8
– – ﹤0.01% 4384
2023
Q4 		$464 Buy
+8
New +$322 ﹤0.01% 4425
2022
Q1 		– Sell
-19
Closed -$3K – 4642
2021
Q4 		$3K Hold
19
– – ﹤0.01% 4082
2021
Q3 		$5K Sell
19
-506
-96% -$148K ﹤0.01% 3942
2021
Q2 		$178K Sell
525
-84
-14% -$31.8K ﹤0.01% 2295
2021
Q1 		$246K Buy
609
+361
+146% +$175K ﹤0.01% 2044
2020
Q4 		$165K Buy
248
+229
+1,205% +$127K ﹤0.01% 2182
2020
Q3 		$9K Hold
19
– – ﹤0.01% 3541
2020
Q2 		$11K Buy
+19
New +$6.49K ﹤0.01% 3441

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
AV
Alamea Verwaltungs Edison, New Jersey $125M AUM 27.56% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PNC Financial Services Group's MRSN Position: Q3 2025 in Review

PNC Financial Services Group sold out of Mersana Therapeutics (MRSN) in Q3 2025, closing a stake of 36 shares — an estimated $264 sold.

PNC Financial Services Group first reported a position in MRSN in Q2 2020 and held it in 14 quarters. The position peaked at $246K in Q1 2021. 49 funds tracked by Wall St. Rank hold MRSN as of Q3 2025.

  • PNC Financial Services Group reported no remaining Mersana Therapeutics position as of Q3 2025 after selling out during the quarter.
  • PNC Financial Services Group sold 36 Mersana Therapeutics shares in Q3 2025, an estimated $264.
  • PNC Financial Services Group first reported a position in Mersana Therapeutics in Q2 2020 and held it in 14 quarters.
  • PNC Financial Services Group's Mersana Therapeutics position peaked at $246K in Q1 2021.
  • 49 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2025.

Based on PNC Financial Services Group's 13F filing for Q3 2025, filed 7 Nov 2025.